Micellar colloidal pharmaceutical composition containing a lipophilic active principle
First Claim
Patent Images
1. A self-micro emulsifying pharmaceutical composition for oral use comprising:
- at least one lipophilic active principle, at least one surfactant having a hydrophilic/lipophilic balance of less than 16, at least one cosurfactant, at least one lipophilic phase, characterized in that;
the lipophilic active principle(s) have a log P greater than 2, the surfactant(s) represent at least 50% by weight of the total weight of said composition, the cosurfactant(s) are chosen from the good solvents for said active principle(s), the lipophilic phase is optionally surface-active and represents less than 0.5 to 4.5% by weight of the total weight of said composition and has an HLB of less than or equal to 6, and when the active principle is different from a retinoid, then said composition additionally comprises a nonsurfactant oily phase representing from 1 to 12% of the total weight of said composition.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention concerns novel pharmaceutical compositions capable of comprising micelles containing at least a very lipophilic principle, enabling to enhance bioavailability of active principles insoluble in aqueous solvents called MIDDS® (Micellar Improved Drug Delivery Solutions).
91 Citations
23 Claims
-
1. A self-micro emulsifying pharmaceutical composition for oral use comprising:
-
at least one lipophilic active principle, at least one surfactant having a hydrophilic/lipophilic balance of less than 16, at least one cosurfactant, at least one lipophilic phase, characterized in that;
the lipophilic active principle(s) have a log P greater than 2, the surfactant(s) represent at least 50% by weight of the total weight of said composition, the cosurfactant(s) are chosen from the good solvents for said active principle(s), the lipophilic phase is optionally surface-active and represents less than 0.5 to 4.5% by weight of the total weight of said composition and has an HLB of less than or equal to 6, and when the active principle is different from a retinoid, then said composition additionally comprises a nonsurfactant oily phase representing from 1 to 12% of the total weight of said composition. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
Specification